Page 1392 - Williams Hematology ( PDFDrive )

1366 Part X: Malignant Myeloid Diseases Chapter 87: Myelodysplastic Syndromes 1367

286. Padmanabhan A, Baker JA, Zirpoli G, et al: Acute myeloid leukemia and myelodys- 314. Westers TM, Alhan C, Chamuleau ME, et al: Aberrant immunophenotype of blasts in
plastic syndrome following breast cancer: Increased frequency of other cancers and of myelodysplastic syndromes is a clinically relevant biomarker in predicting response to
cancers in multiple family members. Leuk Res 2008;32(12):1820–1823, 2000. growth factor treatment. Blood 115(9):1779–1784, 2010.
287. Hake CR, Graubert TA, Fenske TS: Does autologous transplantation directly increase 315. Saft L, Karimi M, Ghaderi M, et al: P53 protein expression independently predicts out-
the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant come in patients with lower-risk myelodysplastic syndromes with del(5q). Haematolog-
39(2):59–70, 2007. ica 99(6):1041–1049, 2014.
288. Palumbo A, Bringhen S, Kumar SK, et al: Second primary malignancies with lenalido- 316. Bejar R, Stevenson K, Abdel-Wahab O, et al: Clinical effect of point mutations in myel-
mide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data. odysplastic syndromes. N Engl J Med 364(26):2496–2506, 2011.
Lancet Oncol 15(3):333–342, 2014. 317. Greenberg PL, Attar E, Bennett JM, et al: Myelodysplastic syndromes: Clinical practice
289. Chakraborty S, Sun CL, Francisco L, et al: Accelerated telomere shortening precedes guidelines in oncology. J Natl Compr Canc Netw 11(7):838–874, 2013.
development of therapy-related myelodysplasia or acute myelogenous leukemia after 318. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for
autologous transplantation for lymphoma. J Clin Oncol 27(5):791–798, 2009. modification of the International Working Group (IWG) response criteria in myelo-
290. Fukumoto JS, Greenberg PL: Management of patients with higher risk myelodysplastic dysplasia. Blood 108(2):419–425, 2006.
syndromes. Crit Rev Oncol Hematol 56(2):179–192, 2005. 319. Steensma DP, Heptinstall KV, Johnson VM, et al: Common troublesome symptoms
291. Senent L, Arenillas L, Luno E, Ruiz JC, Sanz G, Florensa L: Reproducibility of the World and their impact on quality of life in patients with myelodysplastic syndromes (MDS):
Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica Results of a large internet-based survey. Leuk Res 32(5):691–698, 2008.
98(4):568–575, 2013. 320. Sekeres MA, Maciejewski JP, List AF, et al: Perceptions of disease state, treatment out-
292. Font P, Loscertales J, Benavente C, et al: Inter-observer variance with the diagnosis of comes, and prognosis among patients with myelodysplastic syndromes: Results from
myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol an internet-based survey. Oncologist 16(6):904–911, 2011.
92(1):19–24, 2013. 321. Abel GA, Klaassen R, Lee SJ, et al: Patient-reported outcomes for the myelodysplastic
293. Greenberg PL, Attar E, Bennett JM, et al: Myelodysplastic syndromes: Clinical practice syndromes: A new MDS-specific measure of quality of life. Blood 123(3):451–452, 2014.
guidelines in oncology. J Natl Compr Canc Netw 11(7):838–874, 2013. 322. Jansen AJ, Essink-Bot ML, Beckers EA, et al: Quality of life measurement in patients
294. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al: Diagnosis and treatment of pri- with transfusion-dependent myelodysplastic syndromes. Br J Haematol 121(2):
mary myelodysplastic syndromes in adults: Recommendations from the European 270–274, 2003.
LeukemiaNet. Blood 122(17):2943–2964, 2013. 323. Kornblith AB, Herndon JE 2nd, Silverman LR, et al: Impact of azacytidine on the qual-
295. Garcia-Manero G, Shan J, Faderl S, et al: A prognostic score for patients with lower risk ity of life of patients with myelodysplastic syndrome treated in a randomized phase III
myelodysplastic syndrome. Leukemia 22(3):538–543, 2008. trial: A Cancer and Leukemia Group B study. J Clin Oncol 20(10):2441–2452, 2002.
296. Kantarjian H, O’Brien S, Ravandi F, et al: Proposal for a new risk model in myelodys- 324. Lindquist KJ, Danese MD, Mikhael J, et al: Health care utilization and mortality among
plastic syndrome that accounts for events not considered in the original International elderly patients with myelodysplastic syndromes. Ann Oncol 22(5):1181–1188, 2011.
Prognostic Scoring System. Cancer 113(6):1351–1361, 2008. 325. Hellstrom-Lindberg E, Malcovati L: Supportive care and use of hematopoietic growth
297. Malcovati L, Della Porta MG, Strupp C, et al: Impact of the degree of anemia on factors in myelodysplastic syndromes. Semin Hematol 45(1):14–22, 2008.
the outcome of patients with myelodysplastic syndrome and its integration into the 326. Oliva EN, Schey C, Hutchings AS: A review of anemia as a cardiovascular risk factor in
WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96(10): patients with myelodysplastic syndromes. Am J Blood Res 1(2):160–166, 2011.
1433–1440, 2011. 327. Fakhry SM, Fata P: How low is too low? Cardiac risks with anemia. Crit Care 8 Suppl
298. Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic scoring 2:S11–S14, 2004.
system for myelodysplastic syndromes. Blood 120(12):2454–2465, 2012. 328. Hajjar LA, Vincent JL, Galas FR, et al: Transfusion requirements after cardiac surgery:
299. Neukirchen J, Lauseker M, Blum S, et al: Validation of the revised International Prog- The TRACS randomized controlled trial. JAMA 304(14):1559–1567, 2010.
nostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multi- 329. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled
center study. Leuk Res 38(1):57–64, 2014. clinical trial of transfusion requirements in critical care. Transfusion Requirements
300. Voso MT, Fenu S, Latagliata R, et al: Revised International Prognostic Scoring Sys- in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med
tem (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes 340(6):409–417, 1999.
significantly better than IPSS and WHO Prognostic Scoring System: Validation by 330. Hogshire L, Carson JL: Red blood cell transfusion: What is the evidence when to trans-
the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 31(21): fuse? Curr Opin Hematol 20(6):546–551, 2013.
2671–2677, 2013. 331. Pascal L, Beyne-Rauzy O, Brechignac S, et al: Cardiac iron overload assessed by T2*
301. Zeidan AM, Lee JW, Prebet T, et al: Comparison of the prognostic utility of the revised magnetic resonance imaging and cardiac function in regularly transfused myelodys-
International Prognostic Scoring System and the French Prognostic Scoring Sys- plastic syndrome patients. Br J Haematol 162(3):413–415, 2013.
tem in azacitidine-treated patients with myelodysplastic syndromes. Br J Haematol 332. Chacko J, Pennell DJ, Tanner MA, et al: Myocardial iron loading by magnetic reso-
166(3):352–359, 2014. nance imaging T2* in good prognostic myelodysplastic syndrome patients on long-
302. Sekeres MA, Swern AS, Fenaux P, et al: Validation of the IPSS-R in lenalidomide-treated, term blood transfusions. Br J Haematol 138(5):587–593, 2007.
lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer J 4(4):e242, 333. Kantarjian H, Giles F, List A, et al: The incidence and impact of thrombocytopenia in
2014. myelodysplastic syndromes. Cancer 109(9):1705–1714, 2007.
303. Della Porta MG, Alessandrino EP, Bacigalupo A, et al: Predictive factors for the out- 334. Cullen M, Baijal S: Prevention of febrile neutropenia: Use of prophylactic antibiotics. Br
come of allogeneic transplantation in patients with MDS stratified according to the J Cancer 101 Suppl 1:S11–S14, 2009.
revised IPSS-R. Blood 123(15):2333–2342, 2014. 335. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J: Acyclovir prophylaxis
304. Steensma DP, Tefferi A: Risk-based management of myelodysplastic syndrome. Oncol- and fever during remission-induction therapy of patients with acute myeloid leukemia:
ogy (Williston Park) 21(1):43–54; discussion 57–58, 62, 2007. A randomized, double-blind, placebo-controlled trial. J Clin Oncol 15(6):2269–2274,
305. Sekeres MA: How to manage lower-risk myelodysplastic syndromes. Leukemia 1997.
26(3):390–394, 2012. 336. Cornely OA, Maertens J, Winston DJ, et al: Posaconazole vs. fluconazole or itraconazole
306. Sekeres MA, Cutler C: How we treat higher-risk myelodysplastic syndromes. Blood prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359, 2007.
123(6):829–836, 2014. 337. Steensma DP, Stone RM: Practical recommendations for hypomethylating agent
307. Fenaux P, Ades L: How we treat lower-risk myelodysplastic syndromes. Blood therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am
121(21):4280–4286, 2013. 24(2):389–406, 2010.
308. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with 338. Cornely OA, Bohme A, Buchheidt D, et al: Primary prophylaxis of invasive fungal
chromosome 5q deletion. N Engl J Med 355(14):1456–1465, 2006. infections in patients with hematologic malignancies. Recommendations of the Infec-
309. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al: A validated decision model tious Diseases Working Party of the German Society for Haematology and Oncology.
for treating the anaemia of myelodysplastic syndromes with erythropoietin + granu- Haematologica 94(1):113–122, 2009.
locyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 339. Mattiuzzi GN, Kantarjian H, Faderl S, et al: Amphotericin B lipid complex as pro-
120(6):1037–1046, 2003. phylaxis of invasive fungal infections in patients with acute myelogenous leukemia
310. Traina F, Visconte V, Elson P, et al: Impact of molecular mutations on treatment and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):
response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 581–589, 2004.
28(1):78–87, 2014. 340. Cazzola M, Malcovati L: Myelodysplastic syndromes—Coping with ineffective hemato-
311. Itzykson R, Kosmider O, Cluzeau T, et al: Impact of TET2 mutations on response rate to poiesis. N Engl J Med 352(6):536–538, 2005.
azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. 341. Malcovati L: Impact of transfusion dependency and secondary iron overload on the sur-
Leukemia 25(7):1147–1152, 2011. vival of patients with myelodysplastic syndromes. Leuk Res 31 (Suppl 3):S2–S6, 2007.
312. Saunthararajah Y, Nakamura R, Wesley R, et al: A simple method to predict response 342. Chee CE, Steensma DP, Wu W, et al: Neither serum ferritin nor the number of red blood
to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts.
102(8):3025–3027, 2003. Am J Hematol 83(8):611–613, 2008.
313. Sekeres MA, Giagounidis A, Kantarjian H, et al: Development and validation of a 343. Leitch HA, Chan C, Leger CS, et al: Improved survival with iron chelation therapy for
model to predict platelet response to romiplostim in patients with lower-risk myelo- red blood cell transfusion dependent lower IPSS risk MDS may be more significant in
dysplastic syndromes. Br J Haematol 167(3):337–345, 2014. patients with a non-RARS diagnosis. Leuk Res 36(11):1380–1386, 2012.

Kaushansky_chapter 87_p1341-1372.indd 1367 9/21/15 11:06 AM